Golden
Biosortia Pharmaceuticals

Biosortia Pharmaceuticals

Biosortia is a therapeutics, agrochemical and cosmetics company developing products from microbial small molecules through microbiome mining.

Biosortia is a therapeutics, agrochemical and cosmetics company developing products from microbial small molecules through microbiome mining. Biosortia establishes libraries of natural molecule activity and derivatives from microorganisms extracted from the natural world. Biosortia is in the JLABS incubator and received a $1 million annual recurring revenue (ARR) contract with the Department of Homeland Security.

As part of their cancer drug discovery research Biosortia tests compounds isolated from microorganisms on cancer cell lines. Biosortia sampled from cyanobacterial blooms in Buckeye Lake and Grand Lake St. Marys in Ohio and disovered a new series of cardiotoxic steroids. The group also discovered new cytotoxic compounds from a Microcystis aeruginosa bloom.

Timeline

October 28, 2018

Cyanobufalins: Cardioactive Toxins from Cyanobacterial Blooms

May 30, 2018

Microcystins Containing Doubly Homologated Tyrosine Residues from a Microcystis aeruginosa Bloom: Structures and Cytotoxicity

August 14, 2017

Leidos and Biosortia Pharmaceuticals Execute Memorandum of Understanding

MOU to explore a new business relationship focused on leveraging assets and drug discovery capabilities for immuno-oncology application

People

Name
Role
LinkedIn

Annakaisa Elo

Employee

Guy T. Carter

Employee, CSO

Ray Shealy

Investor

Ray Shealy

Investor

Roger Vaughan

Investor

Ross Youngs

Founder, CEO

Russell Brand

Investor

Further reading

Title
Author
Link
Type
Date
+ Add new row

Documentaries, videos and podcasts

Title
Date
Link

The Donna Drake Show Live It Up with Ross O Youngs on Biosortia Pharmaceutical

Companies

Company
CEO
Location
Products/Services
+ Add new row

References